Personalised Ovarian Cancer Vaccine Passes Early Safety TestBy Elspeth HamiltonOctober 16, 2026 A phase 1 trial of the personalised NeoVax vaccine with nivolumab in ovarian cancer found the approach feasible with acceptable safety. Here is what it means.
